Comparison of Apnea Tolerance in Two Positions of Patients With BMI 30-40
- Conditions
- General Surgery
- Interventions
- Other: 25° head-up positionOther: 55° head-up position
- Registration Number
- NCT03056820
- Lead Sponsor
- University of Kansas Medical Center
- Brief Summary
The purpose of this study is to compare the effect of the 25° head-up position versus the 55° head-up position on tolerable apnea time (TAT) after induction of general anesthesia in patients with a body mass index (BMI) of 30-40.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 74
- American Society of Anesthesiologists (ASA) physical status I-III
- Body Mass Index (BMI) of 30-40
- Scheduled for an elective surgery that requires tracheal intubation
- Patients with abnormalities of the upper airway that require awake tracheal intubation
- Asthma
- Chronic obstructive pulmonary disease
- Congestive heart failure
- Pregnant patients
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description A - 25° head-up position 25° head-up position Participants will be positioned at 25° angle for procedure. B - 55° head-up position 55° head-up position Participants will be positioned at 55° angle for procedure.
- Primary Outcome Measures
Name Time Method Tolerable Apnea Time (TAT) Time between start of induction of general anesthesia (SpO2 100%) to decline of SpO2 94%, up to eight minutes Measure of the TAT between groups to determine if the TAT is a function of the participant's position.
- Secondary Outcome Measures
Name Time Method Length of time to intubation (TTI) Time between start of the tracheal intubation procedure to completion of tracheal intubation, up to 2 minutes Peripheral arterial hemoglobin oxygen saturation (SpO2) trough Time until SpO2 decreased to 92%, up to 8 minutes Measure of the rebound SpO2. It is the lowest SpO2 reading reached subsequent to start of mechanical ventilation at the SpO2 value of 94% and it represents final completion of SpO2 decline.
Trial Locations
- Locations (1)
University of Kansas Medical Center
🇺🇸Kansas City, Kansas, United States